Randomized comparison of interferon-alpha vs chemotherapy in patients with Philadelphia-negative chronic myelogenous leukemia (CML).

被引：0
|
作者：
Hochhaus, A [1 ]
Hehlmann, R [1 ]
Bartram, CR [1 ]
Heimpel, H [1 ]
Reiter, A [1 ]
Berger, U [1 ]
Ansari, H [1 ]
Skladny, H [1 ]
Heinze, B [1 ]
Hossfeld, DK [1 ]
机构：
[1] UNIV HEIDELBERG,KLINIKUM MANNHEIM,GERMAN CML STUDY GRP,MED KLIN 3,MANNHEIM,GERMANY
来源：
BLOOD | 1997年 / 90卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2298 / 2298
页数：1
相关论文
共 50 条
  • [31] Interferon-α protects Philadelphia-negative hematopoietic progenitors from exhaustion in chronic myeloid leukemia (CML) patients with cytogenetic response.
    Frassoni, F
    Podestà, M
    Piaggio, G
    Rosti, V
    Pitto, A
    Figari, O
    Soracco, M
    Bergamaschi, G
    Gualandi, F
    Lamparelli, T
    Berisso, G
    Bacigalupo, A
    Cazzola, M
    BLOOD, 1998, 92 (10) : 250A - 251A
  • [32] THERAPEUTIC PROGRESS AND COMPARATIVE ASPECTS IN CHRONIC MYELOGENOUS LEUKEMIA (CML) - INTERFERON-ALPHA VS HYDROXYUREA VS BUSULFAN AND EXPRESSION OF MMTV-RELATED ENDOGENOUS RETROVIRAL SEQUENCES IN CML
    HEHLMANN, R
    KISTER, P
    WILLER, A
    SIMON, M
    SCHENK, M
    SEIFARTH, W
    PAPAKONSTANTINOU, G
    SAUSSELE, S
    KOLB, HJ
    ANSARI, H
    LEIBMOSCH, C
    LEUKEMIA, 1994, 8 : S127 - S132
  • [33] Autologous transplantation with Philadelphia-negative progenitor cells for patients with chronic myeloid leukaemia (CML) failing to attain a cytogenetic response to alpha interferon
    NC McBride
    JD Cavenagh
    AC Newland
    DM Lillington
    C Murrell
    SM Kelsey
    Bone Marrow Transplantation, 2000, 26 : 1165 - 1172
  • [34] Comparison of molecular methods to monitor response in chronic myelogenous leukemia (CML) patients treated with interferon-alpha.
    Hochhaus, A
    Reiter, A
    Skladny, H
    Lin, F
    Hehlmann, R
    Goldman, JM
    Cross, NCP
    EXPERIMENTAL HEMATOLOGY, 1996, 24 (09) : 578 - 578
  • [35] Interferon alpha (IFN) and cyclic intensive chemotherapy (CIC) for chronic phase (CP) chronic myelogenous leukemia (CML).
    Giles, FJ
    Talpaz, M
    O'Brien, SM
    Rios, MB
    Kantarjian, HM
    BLOOD, 1999, 94 (10) : 274B - 274B
  • [36] Quantification of residual disease in chronic myelogenous leukemia (CML) patients on interferon-alpha therapy by competitive polymerase chain reaction.
    Hochhaus, A
    Reiter, A
    Skladny, H
    Lin, F
    Mason, PJ
    vanRhee, F
    Shepherd, PCA
    Allan, NC
    Hehlmann, R
    Goldman, JM
    Cross, NCP
    BLOOD, 1995, 86 (10) : 1064 - 1064
  • [37] Beyond chronic myelogenous leukemia - Potential role for imatinib in Philadelphia-negative myeloproliferative disorders
    Cortes, J
    Kantarjian, H
    CANCER, 2004, 100 (10) : 2064 - 2078
  • [38] Autologous transplantation with Philadelphia-negative progenitor cells for patients with chronic myeloid leukaemia (CML) failing to attain a cytogenetic response to alpha interferon
    McBride, NC
    Cavenagh, JD
    Newland, AC
    Lillington, DM
    Murrell, C
    Kelsey, SM
    BONE MARROW TRANSPLANTATION, 2000, 26 (11) : 1165 - 1172
  • [39] Effect of interferon-alpha (IFN-A) therapy on bone marrow (BM) fibrosis in chronic myelogenous leukemia (CML)
    Wilhelm, M
    Ramos, CM
    OBrien, S
    Pierce, S
    Keating, M
    Talpaz, M
    Kantarjian, H
    BLOOD, 1996, 88 (10) : 3537 - 3537
  • [40] A potential mechanism for the resistance of interferon-alpha treatment in chronic myelogenous leukemia patients.
    Henderson, Y
    Deisseroth, AB
    JOURNAL OF INVESTIGATIVE MEDICINE, 1996, 44 (03) : A232 - A232
12345